Form 8-K Horizon Pharma plc For: Aug 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall Street ends choppy session lower as tech shares drop
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
- Oil prices fall 1% to 4-month lows as progress in US-Iran talks cools supply concerns
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
BMO Capital Positive on Horizon Pharma (HZNP) Amid CVS/Caremark News; Affirms at 'Outperform'
August 2, 2016 12:38 PM EDTBMO Capital affirms Horizon Pharma (Nasdaq: HZNP) at Outperform with a price target of $29 after the company announced that two of its primary care products Duexis and Vimovo were removed from the 2017 CVS/Caremark exclusion list.
Analyst Gary Nachman commented today, We view this announcement as an important win for HZNP. It demonstrates that it is improving its execution on the managed care front as... More
Horizon Pharma (HZNP) Says DUEXIS and VIMOVO Will be Covered by CVS/Caremark
August 2, 2016 7:13 AM EDTHorizon Pharma (NASDAQ: HZNP) disclosed the following on Tuesday morning:
Item 7.01 Regulation FD Disclosure.
Horizon Pharma has secured covered status for DUEXIS and VIMOVO with CVS/Caremark. The Company has been informed that beginning January 1, 2017, DUEXIS and VIMOVO will be removed from the CVS/Caremark exclusion list.
... More